Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6NUCA)

Drug Name
ADR-851 Drug Info
Synonyms
Adr 851; 123805-17-4; UNII-303JW6Z3QJ; 303JW6Z3QJ; Adr-851; PCBGZTCWZUGEJX-QRPNPIFTSA-N; AC1L2WPB; SCHEMBL8785455; DTXSID00154097; 4-Amino-5-chloro-N-(2-pyrrolidinylmethyl)-2,3-dihydrobenzofuran-7-carboxamide hcl; KB-289941; 4-amino-5-chloro-N-[[(2S)-pyrrolidin-2-yl]methyl]-2,3-dihydro-1-benzofuran-7-carboxamide hydrochloride; 7-Benzofurancarboxamide, 4-amino-5-chloro-2,3-dihydro-N-(2-pyrrolidinylmethyl)-, monohydrochloride, (S)-; (S)-4-amino-5-chloro-N-(2-pyrrolidinylmethyl)-2,3-dihydrobenzo[b]furan-7-carboxamide hydro
Indication
Disease Entry ICD 11 Status REF
Nausea and vomiting MD90 Phase 1 [1]
Cross-matching ID
PubChem CID
130053
CAS Number
CAS 123805-17-4
TTD Drug ID
DM6NUCA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 3 receptor (5HT3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ondansetron DMOTQ1I Chemotherapy-induced nausea MD90 Approved [3]
Granisetron DMIUW25 Malignant glioma 2A00.0 Approved [4]
Ramosetron DMH7GN8 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [5]
Y-25130 DMDPM7R Nausea and vomiting MD90 Approved [6]
Renzapride DM7HQNX Irritable bowel syndrome DD91.0 Phase 3 [7]
LITOXETINE DMKZRBP Mood disorder 6A60-6E23 Phase 3 [8]
Zatosetron maleate DMWDEFC Anxiety disorder 6B00-6B0Z Phase 3 [9]
Pancopride DMIRYU9 Nausea MD90 Phase 3 [10]
Lerisetron DMOTCIU Nausea MD90 Phase 3 [11]
Lintopride DMSHGWN Nausea MD90 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 3 receptor (5HT3R) TTNXLKE NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001323)
2 Analgesic effects of S and R isomers of the novel 5-HT3 receptor antagonists ADR-851 and ADR-882 in rats. Eur J Pharmacol. 1991 Oct 29;204(1):117-9.
3 Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70.
4 New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7.
5 Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12.
6 The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305.
7 Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
8 Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
9 Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31.
10 Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64.
11 Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
12 The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.